Clinical Trials Directory

Trials / Completed

CompletedNCT00942240

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

A Phase I, Double-Masked, Multiple Rising Dose Study of ACU-4429 in Healthy Male and Female Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Kubota Vision Inc. · Industry
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of repeated doses of a new investigational drug (ACU-4429) in healthy human subjects.

Conditions

Interventions

TypeNameDescription
DRUGACU-4429administered orally once a day for 14 days
DRUGmatching placebo tabletadministered orally once a day for 14 days

Timeline

Start date
2009-07-01
Primary completion
2010-04-01
Completion
2010-04-01
First posted
2009-07-20
Last updated
2012-01-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00942240. Inclusion in this directory is not an endorsement.